检索结果-南通市图书馆

Comparing the efficacy of different dexamethasone regimens for maintenance treatment of multiple myeloma in standard-risk patients non-eligible for transplantation

引用

World Journal of Clinical Cases 2022年第32期10卷 11712-11725页

作者： Sai-Ling Hu Min Liu Jun-Yu Zhang Department of Cardiology Lishui Central HospitalLishui 323000Zhejiang ProvinceChina Department of Hematology Lishui Municipal Central HospitalLishui 323000Zhejiang ProvinceChina

BACKGROUND Multiple myeloma(MM)is a plasma cell malignancy,while MM outcomes have significantly improved due to novel agents and combinations,MM remains an incurable *** key goal of treatment in MM is to achieve a maximal response and the subsequent consolidation of response after initial *** studies analyzed an improved progression-free survival(PFS)following lenalidomide alone maintenance versus placebo or observation after autologous stem cell transplant(ASCT)in patients with *** the SWOG S0777 clinical trial,patients newly diagnosed with MM(NDMM)without ASCT received lenalidomide plus low-dose dexamethasone(DXM)maintenance until progressive disease,where PFS and overall survival(OS)were significantly *** the present study,we assessed the efficacy and toxicity of the different doses of DXM combined with lenalidomide for maintenance treatment of NDMM for transplant noneligible patients in the standard-risk *** To investigate the efficacy and adverse effects of different administration modes of DXM combined with lenalidomide for maintenance treatment of MM in standard-risk patients ineligible for *** A total of 96 MM patients were enrolled in this study,among whom 48 patients received maintenance treatment that consisted of oral administration of 25 milligrams(mg)of lenalidomide from days 1-21 and 40 mg of DXM on days 1,8,15,and 22(DXM 40 mg group),repeated every 4 *** group was treated with oral administration of 25 mg of lenalidomide from days 1-21 and 20 mg of DXM on days 1-2,8-9,15-16,and 22-23(DXM 20 mg group),which was also repeated every 4 *** The median PFS was 37.25 mo in the DXM 40.00 mg group and 38.17 mo in the DXM 20 mg group(P=0.171).The median OS was 50.78 mo in the DXM 40 mg group and 51.69 mo in the DXM 20 mg group(P=0.171).Fourteen patients in the DXM 40 mg group and 6 patients in the DXM 20 mg group suffered from adverse gastrointestinal reactions after the oral administration o

关键词： Dexamethasone maintenance treatment Multiple myeloma Efficacy Toxicity

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Investigation of cost-effectiveness of highway asphalt pavement maintenance treatments based on rutting development analysis

引用

Journal of Southeast University(English Edition) 2014年第3期30卷 343-347页

作者：李红梅倪富健东南大学交通学院南京210096

To investigate the cost-effectiveness of different maintenance treatments of highways in Jiangsu Province, the historical pavement maintenance records, traffic load information and pavement performance data in the pavement management system （PMS） are recorded and analyzed. Compared with the growth model, the linear model, the logarithm model and the exponential model, the cubic model has higher regression accuracy R2 and it can capture the sigmoid shape of the deterioration curve. So it is selected to simulate the pavement rotting development. The benefit over cost ratio is calculated to quantify the treatment cost- effectiveness. The analysis results show that thin hot mix asphalt （HMA） overlays and micro surfacing are more cost- effective than the. other two treatments on light and moderate traffic roads. Hot in-place recycling and thick HMA overlays have much longer service lives and greater cost-effectiveness under heavy or extra heavy traffic.

关键词： asphalt pavement maintenance treatment cumulative equivalent single axle loads cubic model cost-effectiveness

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Adalimumab in ulcerative colitis: Two cases of mucosal healing and clinical response at two years

引用

World Journal of Gastroenterology 2009年第30期15卷 3814-3816页

作者： Manuel Barreiro-de Acosta Aurelio Lorenzo Juan Enrique Dominguez-Muoz Department of Gastroenterology University Hospital of Santiago de CompostelaC/Choupanas/nE-15706-Santiago de CompostelaSpain

Infliximab (IFX) is currently the only biologic therapy used in the treatment of moderate-to-severe ulcerative colitis (UC). In the years to come, more biologic therapies will have a role in the management of moderate-to-severe UC. We report on two patients with steroid-dependent UC who, due to adverse reactions to IFX, have been under therapy with adalimumab for two years. Both patients received concomitant immunosuppressive treatment. Long term clinical remission and mucosal healing are described.

关键词： Adalimumab Ulcerative colitis Mucosalhealing maintenance treatment

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Are we giving azathioprine too much time?

引用

World Journal of Gastroenterology 2008年第36期14卷 5519-5522页

作者： Fernando Gomollón Santiago García López Department of Digestive Diseases Clinic University Hospital "Lozano Blesa" CIBEREHD IACS Zaragoza Spain Department of Digestive Diseases University Hospital "Miguel Servet" Zaragoza Spain

Azathioprine is currently the key drug in the maintenance treatment of inflammatory bowel diseases. However, there are still some practical issues to be resolved: one is how long we must maintain the drug. Given that inflammatory bowel diseases are to date chronic, non-curable conditions, treatment should be indefinite and only the loss of efficacy or the appearance of serious side effects may cause withdrawal. As regards to efficacy and their maintenance over time, evidence supports the continuous usefulness of the drug in the long term: in fact its withdrawal very substantially increases the risk of relapse. About side effects, azathioprine is a relatively well tolerated drug and even indefinite use seems safe. The main theoretical risks of prolonged use would be the myelotoxicity, hepatotoxicity, and the development of cancer. In fact, serious bone marrow suppression or serious liver damage are uncommon, and can be minimized with proper use of the drug. Recent metanalysis suggests that the risk of lymphoma is real, but the individual risk is rather low, and decision analysis suggests a favorable benefit/risk ratio in the long term. Therefore, in patients with inflammatory bowel diseases in whom azathioprine is effective and well tolerated, the drug should not be stopped. This recommendation concerns the use of azathioprine as a single maintenance drug, and is not necessarily applicable to patients receiving concomitant biological therapy.

关键词： Azathioprine Inflammatory bowel diseases maintenance treatment

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Recent advances in the treatment of opioid use disorders–focus on long-acting buprenorphine formulations

引用

World Journal of Psychiatry 2021年第9期11卷 543-552页

作者： Michael Soyka Andreas G Franke Psychiatric Hospital University of MunichMünchen 80336Germany University of Applied Labour Studies Mannheim 68163Germany

Oral methadone or sublingual buprenorphine are first-line medications for pharmacotherapy of opioid use disorders(OUDs).Three long-acting buprenorphine depot or implant formulations are currently available for the treatment of OUDs:(1)CAM 2038(Buvidal)for subcutaneous weekly and monthly application;(2)RBP-6000(Sublocade^(TM))as a monthly depot formulation;and(3)A six-month buprenorphine implant[Probuphine^(TM)].The pharmacology,clinical efficacy and prospects of these medications are discussed.

关键词： Opioids Opioid dependence maintenance treatment Methadone Buprenorphine Depot Implant

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Effect of Feitai Capsule(肺泰胶囊) on Quality of Life and Progression-Free Survival of Patients with Unresectable Non-Small Cell Lung Cancer

引用

Chinese Journal of Integrative Medicine 2012年第2期18卷 106-111页

作者：余宗阳刘志臻欧阳学农杜建戴西湖陈曦赵忠全王文武李捷 Department of Oncology Fuzhou General HospitalNanjing Military Command Fujian Academy of Integrative Medicine Fujian University of Traditional Chinese Medicine

Objective： To examine the effect of a Chinese medicinal herbal formula （Feitai Capsule, 肺泰胶囊） on the quality of life （QOL） and progression-free survival （PFS） of patients with unresectable non-small cell lung cancer （NSCLC）. Methods： Sixty-two patients were randomly divided into the treatment group （31 cases） and the control group （31 cases）. For the treatment group, 4 capsules （1.2 g/capsule） of Feitai Capsule were administered 3 times a day after meals for 3 weeks; then no drug was administered for 1 week. This schedule was continued for at least 3 more cycles （12 weeks totally）. If there were no obvious toxic reactions, the treatment was extended. The patients were evaluated at least once every 8 weeks until progressive dJsease （PD）. For the control group, the regular follow-up and evaluation were performed at least once every 8 weeks until PD. Clinical symptoms, objective response, physical constitution and energy, QOL, and PFS were evaluated regularly. Analysis of variance （ANOVA）, a non-parametric test, and analysis of covariance were used to compare clinical features, amelioration of clinical symptoms, physical constitution and energy, and QOL. Kaplan- Meier analysis was used to compare the two-group PFS. Results： Sixty patients finished the final evaluation, with 30 patients in each group. Baseline characters between groups were not significantly different （P〉0.05）. The control group had a 36.7% improvement in clinical symptoms, while the treatment group had a 73.3% improvement. This difference was statistically significant （Z=-2.632, P=0.008）. The control group had a 26.7% improvement in the Karnofsky performance status （KPS）, while the treatment group had a 53.4% improvement. This was also significantly different （Z=-2.182, P=0.029）. A comparative analysis indicated a positive correlation （r=0.917, P〈0.001）. Compared with the control group, QOL in the treatment group was significantly improved, except in the social/family condition and doctor-patient relat

关键词： non-small cell Lung cancer Chinese medicine Feitai Capsule maintenance treatment quality oflife progression-free survival

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Systemic chemotherapy for metastatic breast cancer

引用

Oncology and Translational Medicine 2015年第5期1卷 226-232页

作者： Yannan Zhao Biyun Wang Department of Medical Oncology Fudan University Shanghai Cancer Center Department of Oncology Shanghai Medical CollegeFudan University

Breast cancer is the leading cause of cancer among women worldwide and the most common cancer in China. Many factors influence the treatment strategy for metastatic breast cancer （MBC）. Chemotherapy should be administered to patients with hormone receptor-negative tumors, symptomatic visceral metasta- sis, and a short disease-free interval. Sequential single-agent chemotherapy has similar efficacy as combi- nation agents in terms of overall survival and quality of life. Anthracyclines are the cornerstone of first-line treatment for MBC, and taxanes represent the second treatment option after resistance. When progression or intolerable toxicity occurs after optimal treatment, the alternative treatments include capecitabine, vinorel- bine, and gemcitabine. Ixabepilone and eribulin are relatively new effective single agents. A combination of cytotoxic agents for patients with rapid clinical progression can further improve the overall response rate and time to progression compared to single-agent treatment. For patients with MBC who were pretreated with anthracyclines in the neoadjuvant/adjuvant setting, a taxane-containing regimen such as docetaxel plus capecitabine or gemcitabine plus paclitaxel should be administered. Platinum-based therapies such as cisplatin or carboplatin have a role in the treatment of triple-negative breast cancer. Meanwhile, the efficacy of the addition of targeted drugs such as iniparib, bevacizumab, and catuximab to chemotherapy remains unproven. maintenance chemotherapy is routinely recommended in clinical practice at present. Patients who were previously treated with paclitaxel and gemcitabine have better progression-free and overall sur- vival with maintenance chemotherapy according to a Korean phase III clinical trial. Sequential maintenance treatment with capecitabine monotherapy after capecitabine-based combination chemotherapy （X-based X） appears favorable based on a series of domestic studies.

关键词： chemotherapy metastatic breast cancer (MBC) single-agent chemotherapy combination chemotherapy triple-negative breast cancer maintenance treatment

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

The observation of single-agent gemcitabine maintenance therapy in patients with metastatic breast cancer

引用

The Chinese-German Journal of Clinical Oncology 2013年第12期12卷 568-573页

作者： Xiaoran Yin Hongbing Ma Xiaoning Li Zhijun Dai Xinghuan Xue Shuqun Zhang Kaige Liu Yan Diao Yinan Ma Xijing Wang Department of Oncology The Second Affiliated Hospital of Xi’an Jiaotong University Department of Digestion The First Affiliated Hospital of Xi’an Medical University

Objective:The aim of the study was to evaluate the efficacy and tolerability of single-agent gemcitabine in the maintenance treatment of histologically confirmed metastatic breast cancer ***:The 45 patients carried efficacious chemotherapy were divided into maintenance therapy group(n=23) and control group(n=22) according to the different treatment *** in the maintenance therapy group received gemcitabine therapy until 6 cycles,disease progression or adverse effect *** the control group,the patients were given best supportive ***-up was made until disease progression,death or 2 *** short-term clinical efficacy and adverse effects,progression-free survival(PFS) and median survival of recurrence(MSR) of these two groups were compared and ***:Compared with the control group,the experiment group had higher response rate(RR;73.9% vs 31.8%;P0.05).Most of the treatment-related adverse events were mild,and the most common adverse event was hematologic *** 3 cases occurred grades 3–4 neutropenia and 3 cases occurred grades 3–4 *** 1 patient stopped treatment because of grade 3 allergic reaction,and 4 patients required dose reduction for grade 4 adverse *** adverse effects were grades 1–2,and all were recovered after symptomatic *** was no significant side effect which threatened the ***:In the extension maintenance treatment,gemcitabine can consolidate the therapeutic effect in advance and significantly prolong median PFS of metastatic breast cancer *** conclusion,gemcitabine monotherapy with a favorable safety profile is an effective maintenance treatment in metastatic breast cancer patients.

关键词： gemcitabine breast cancer metastasis maintenance treatment chemotherapy

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：